首页> 美国卫生研究院文献>Antiviral Chemistry Chemotherapy >Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors
【2h】

Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors

机译:建立血小板减少症候群病毒抑制剂的抗病毒检测系统并鉴定重度发热

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AimsSevere fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease. SFTS is epidemic in Asia, and its fatality rate is around 30% in Japan. The causative virus severe fever with thrombocytopenia syndrome virus (SFTSV) is a phlebovirus of the family Phenuiviridae (the order Bunyavirales). Although effective treatments are required, there are no antiviral agents currently approved for clinical use. Ribavirin and favipiravir were examined for their anti-SFTSV activity and found to be selective inhibitors of SFTSV replication in vitro. However, their activity was not sufficient. Therefore, it is mandatory to identify novel compounds active against SFTSV. To this end, we have established a safe and rapid assay system for screening selective inhibitors of SFTSV.
机译:目的患有血小板减少症(SFTS)的严重发烧是一种新兴的tick传播传染病。 SFTS在亚洲很流行,在日本,其死亡率约为30%。血小板减少症候群病毒(SFTSV)的致病性病毒是一种严重的发烧病毒,属于苯丙酸病毒科(Bunuivirales)的一种静脉病毒。尽管需要有效的治疗方法,但目前尚无抗病毒药被批准用于临床。检查了利巴韦林和favipiravir的抗SFTSV活性,发现它们是体外SFTSV复制的选择性抑制剂。但是,他们的活动还不够。因此,必须鉴定出对SFTSV有活性的新型化合物。为此,我们建立了一种安全,快速的检测系统,用于筛选SFTSV的选择性抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号